Advaxis, Karolinska Institutet enter collaboration to develop cat allergy vaccine

Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a research collaboration with Professor Marianne van Hage, research group leader and Head of the Clinical Immunology and Allergy Unit and Vice Head of the Department of Medicine at Karolinska Institutet in Stockholm, Sweden. The purpose of this collaboration is to evaluate the potential of Advaxis immunotherapies to treat and prevent allergies in established scientific models of allergic diseases.

“We are very excited about the collaboration with Advaxis and hope to develop an efficient and safe vaccine for cat allergy, which could lead to other allergy treatments in the future”

Prof. Marianne van Hage's research is focused on further understanding the molecular mechanisms of underlying allergic disease and the function of allergens, and to develop new diagnostic markers and new strategies for vaccination. Her work using cat allergy as a model system has resulted in significant insights and understanding to develop treatments and prevention options for allergic responses. Prof. van Hage will be using Advaxis immunotherapies to develop allergy treatments using the models she and her team have developed. If successful, this work may be applied to other allergic diseases.

"The Karolinska Institutet is a world-renowned group of researchers and we are pleased that our immunotherapies may help to better understand allergic responses and potentially provide additional prevention and treatment options," said Advaxis Chairman/CEO Thomas A. Moore.

"We are very excited about the collaboration with Advaxis and hope to develop an efficient and safe vaccine for cat allergy, which could lead to other allergy treatments in the future," commented Prof. Marianne van Hage.